Skip to content
DraconiticResearch
Search Sources API
182,549 studies31 sourcesUpdated 58 min ago
Peer-reviewedCC BYRespirology case reports

Persistent Coronavirus Disease 2019 (COVID‐19) in Patients With Malignant Lymphoma Treated With Anti‐CD20 Antibodies Who Responded to Ensitrelvir: A Report of Three Cases

  • Mika Horie1
  • Tamio Okimoto1
  • Yusuke Okada2
  • Masaya Inoue2
  • Shintaro Shimizu1
  • Hirotoki Tsuda1
  • Kojiro Hata1
  • Takae Okuno1
  • Yoshihiro Amano1
  • Mika Nakao1
  • Kazuhisa Nakashima1
  • Megumi Hamaguchi1
1 more authors
  • Takeshi Isobe1
  1. 1Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine Shimane University Faculty of Medicine Izumo Shimane Japan.
  2. 2Department of Hematology Shimane University Hospital Izumo Japan.
Read full textPDFDOICite

Abstract

Patients with malignant lymphoma receiving anti-CD20 antibody therapy are at high risk of persistent coronavirus disease 2019 (COVID-19), with no established standard treatment. We report three cases of persistent COVID-19 in patients with follicular lymphoma who responded clinically after switching to ensitrelvir following the failure of remdesivir-based treatment. Each patient had multiple relapses and an inadequate response to remdesivir but achieved symptom resolution with ensitrelvir. These cases suggest that switching to an antiviral with a different mechanism of action may be an effective therapeutic strategy for immunocompromised patients when initial antiviral therapies fail.

Related

  1. Persistent neutralizing antibodies against chikungunya virus eight years after infection
    Xue-Li Zhu, Meng-Fei Wang, Meng Kong +11
    Biosafety and healthPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Persistent Malignant Stem Cells Drive Relapse After Transplantation in the Myelodysplastic Neoplasms
    B. Kroger, R. Tamari, C. Gurnari +25
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  3. Predictive value of persistent cerebrospinal fluid antibodies at 12 months for long-term clinical outcomes in pediatric anti-NMDAR encephalitis: a retrospective cohort study
    Hua Yang, Ruling Zhang, Jie Yang +3
    Frontiers in immunologyPeer-reviewedCC BYFull textNeurologyEurope PMCCrossref
  4. CO007 | TPO-RECEPTOR AGONISTS AS AN INDEPENDENT RISK FACTOR FOR VENOUS THROMBOTIC EVENT IN IMMUNE THROMBOCYTOPENIA PATIENTS WITH PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES POSITIVITY
    Mario Biglietto
    Bleeding, Thrombosis and Vascular BiologyPeer-reviewedCC BY-NCFull textCardiovascular medicineDOAJ
  5. Cost-Effectiveness of Ensitrelvir for COVID-19 Post-Exposure Prophylaxis Among High-Risk Household Contacts in Japan: A Model-Based Cost-Utility Analysis
    T. Taniguchi, M. Yahaba, H. Yoshikawa +2
    medRxivPreprintCC BY-NC-NDFull textInfectious diseasemedRxiv

Cite

BibTeXRIS
BibTeX
@article{horie2026persistent,
  title = {{Persistent Coronavirus Disease 2019 (COVID‐19) in Patients With Malignant Lymphoma Treated With Anti‐CD20 Antibodies Who Responded to Ensitrelvir: A Report of Three Cases}},
  author = {Mika Horie and Tamio Okimoto and Yusuke Okada and Masaya Inoue and Shintaro Shimizu and Hirotoki Tsuda and Kojiro Hata and Takae Okuno and Yoshihiro Amano and Mika Nakao and Kazuhisa Nakashima and Megumi Hamaguchi and Takeshi Isobe},
  journal = {Respirology case reports},
  year = {2026},
  month = nov,
  doi = {10.1002/rcr2.70804},
  url = {https://europepmc.org/article/PMC/PMC13727363},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Persistent Coronavirus Disease 2019 (COVID‐19) in Patients With Malignant Lymphoma Treated With Anti‐CD20 Antibodies Who Responded to Ensitrelvir: A Report of Three Cases
AU  - Mika Horie
AU  - Tamio Okimoto
AU  - Yusuke Okada
AU  - Masaya Inoue
AU  - Shintaro Shimizu
AU  - Hirotoki Tsuda
AU  - Kojiro Hata
AU  - Takae Okuno
AU  - Yoshihiro Amano
AU  - Mika Nakao
AU  - Kazuhisa Nakashima
AU  - Megumi Hamaguchi
AU  - Takeshi Isobe
PY  - 2026
DA  - 2026/11/01
JO  - Respirology case reports
DO  - 10.1002/rcr2.70804
UR  - https://europepmc.org/article/PMC/PMC13727363
AB  - Patients with malignant lymphoma receiving anti-CD20 antibody therapy are at high risk of persistent coronavirus disease 2019 (COVID-19), with no established standard treatment. We report three cases of persistent COVID-19 in patients with follicular lymphoma who responded clinically after switching to ensitrelvir following the failure of remdesivir-based treatment. Each patient had multiple relapses and an inadequate response to remdesivir but achieved symptom resolution with ensitrelvir. These cases suggest that switching to an antiviral with a different mechanism of action may be an effective therapeutic strategy for immunocompromised patients when initial antiviral therapies fail.
SN  - 2051-3380
ER  -